Lars Frison

6.2k citations

53 papers · 4.2k indexed · 1 hit paper · h-index 27

Impact in

Internal Medicine top 0.2%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 0.5%
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac electrophysiology and arrhythmias

Papers in ⓘ

Cardiology and Cardiovascular Medicine 35
- Atrial Fibrillation Management and Outcomes 30
- Cardiac electrophysiology and arrhythmias 14
- Cardiac Arrhythmias and Treatments 7
- Antiplatelet Therapy and Cardiovascular Diseases 4
Internal Medicine 16
- Venous Thromboembolism Diagnosis and Management 16

Co-authors: Gregory Y.H. Lip (6 shared papers)Jonathan L. Halperin (4 shared papers)Deirdre A. Lane (3 shared papers)Stuart Pocock (3 shared papers)David Gustafsson (9 shared papers)Ulf G. Eriksson (12 shared papers)Margaretha Grind (5 shared papers)Bengt I. Eriksson (6 shared papers)
Journals: Thrombosis and Haemostasis (5 papers)Clinical Pharmacokinetics (5 papers)Journal of the American Society of Nephrology (3 papers)Stroke (3 papers)Annals of Noninvasive Electrocardiology (2 papers)
Partner nations: Sweden United States United Kingdom

In The Last Decade

Lars Frison

52 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation 2010 · 770 citations

Peers

Countries citing papers authored by Lars Frison

Since Specialization

Citations

This map shows the geographic impact of Lars Frison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Frison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Frison more than expected).

Fields of papers citing papers by Lars Frison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Frison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Frison. The network helps show where Lars Frison may publish in the future.

Co-authors

The 25 scholars most cited alongside Lars Frison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lars Frison Line = papers co-authored together Lars Frison links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation Journal of the American College of Cardiology ·Gregory Y.H. Lip, Lars Frison, Jonathan L. Halperin, Deirdre A. Lane Hit paper breakdown →	2010	770
2	Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation JAMA ·Gregory W. Albers, Hans‐Christoph Diener, Lars Frison, Margaretha Grind, Mark Nevinson, Stephen Partridge, Jonathan L. Halperin, Jay Horrow, S. Bertil Olsson, Palle Petersen, Alec Vahanian	2005	497
3	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design Statistics in Medicine ·Lars Frison, Stuart Pocock	1992	466
4	Identifying Patients at High Risk for Stroke Despite Anticoagulation Stroke ·Gregory Y.H. Lip, Lars Frison, Jonathan L. Halperin, Deirdre A. Lane	2010	347
5	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thrombosis and Haemostasis ·Giancarlo Agnelli, Alexander T. Cohen, Ola E. Dahl, Patrick Mouret, Nadia Rosencher, Christina Eskilson, I Nylander, Lars Frison, Mats ögren, Bengt I. Eriksson, (unknown)	2003	207
6	Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial The Lancet ·Bengt I. Eriksson, Peter Kälebo, David Bergqvisty, Ola E. Dahl, Siv Lindbratt, Anders Bylock, Lars Frison, U G Eriksson, Lennart Welin, David Gustafsson	2002	205
7	A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I Journal of Thrombosis and Haemostasis ·Henry Eriksson, Karin Wåhlander, David Gustafsson, Lennart Welin, Lars Frison, Sam Schulman	2003	128
8	Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects European Journal of Clinical Pharmacology ·Ulf G. Eriksson, Ulf Bredberg, Kristina Gislén, Linda C. Johansson, Lars Frison, Martin Ahnoff, David Gustafsson	2003	116
9	Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta‐analysis of long‐term omeprazole trials Alimentary Pharmacology & Therapeutics ·R. Carlsson, J. P. Galmiche, J. Dent, Lars Lundell, Lars Frison	1997	108
10	Effect of hypertension on anticoagulated patients with atrial fibrillation European Heart Journal ·Gregory Y.H. Lip, Lars Frison, Margaretha Grind, (unknown)	2007	108
11	Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study Journal of the American Society of Nephrology ·Steven Fishbane, Mohamed A. El-Shahawy, Roberto Pecoits‐Filho, Bui Pham Van, Mark T. Houser, Lars Frison, Dustin J. Little, Nicolás Guzmán, Pablo E. Pérgola	2021	108
12	A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I Thrombosis and Haemostasis ·Ann-Christin Arfwidsson, Lars Frison, Ulf G. Eriksson, Anders Bylock, Peter Kälebo, Gunnar Fager, David Gustafsson, Bengt I. Eriksson	2002	94
13	Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects Thrombosis and Haemostasis ·Ulf G. Eriksson, Christer Mattsson, Michael Wolzt, Lars Frison, Gunnar Fager, David Gustafsson, Troy C. Sarich	2002	93
14	Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor Clinical Pharmacokinetics ·Linda C. Johansson, Lars Frison, Ulrika Logren, Gunnar Fager, David Gustafsson, Ulf G. Eriksson	2003	83
15	Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions Clinical Pharmacokinetics ·Eva Bredberg, Tommy B. Andersson, Lars Frison, Annelie Thuresson, Susanne Johansson, Maria Eriksson-Lepkowska, Marita Larsson, Ulf G. Eriksson	2003	83
16	Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVT Thrombosis and Haemostasis ·Henry Eriksson, Lars Frison, Per‐Olof Hansson, Peter Held, Margareta Holmström, Anders Hägg, Torsten Jonsson, Leif Lapidus, Barbro Leijd, Dick Stockelberg, (unknown), A Taghavi, Mona Thorsén, Ulf G. Eriksson	1999	78
17	Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials European Heart Journal ·Mardi Gomberg‐Maitland, Nanette K. Wenger, Jan Feyzi, M Lengyel, Annabelle Santos Volgman, Palle Petersen, Lars Frison, Jonathan L. Halperin	2006	75
18	Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery Thrombosis and Haemostasis ·Göran Larson, Tomas Lindahl, Christer Andersson, Lars Frison, David Gustafsson, Anders Bylock, Bengt I. Eriksson, Karin Wåhlander	2002	61
19	Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality American Heart Journal ·Mardi Gomberg‐Maitland, Lars Frison, Jonathan L. Halperin	2003	58
20	Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD Clinical Journal of the American Society of Nephrology ·Robert Provenzano, Lynda A. Szczech, Robert Leong, Khalil G. Saikali, Ming Zhong, Tyson T. Lee, Dustin J. Little, Mark T. Houser, Lars Frison, John Houghton, Thomas B. Neff	2021	56

About Lars Frison

Lars Frison is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine, Economics and Econometrics, Statistics and Probability and Hematology, having authored 53 papers that have together received 4.2k indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (30 papers), Venous Thromboembolism Diagnosis and Management (16 papers), Cardiac electrophysiology and arrhythmias (14 papers), Cardiac Arrhythmias and Treatments (7 papers), Statistical Methods in Clinical Trials (6 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers), Acute Ischemic Stroke Management (4 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). The work is most often cited by research in Internal Medicine (1.8k citations), Cardiology and Cardiovascular Medicine (2.9k citations), Hematology (474 citations), Statistics and Probability (180 citations) and Gastroenterology (110 citations). Lars Frison has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Gregory Y.H. Lip, Jonathan L. Halperin, Deirdre A. Lane, Stuart Pocock, David Gustafsson, Ulf G. Eriksson, Margaretha Grind, Bengt I. Eriksson, Gunnar Fager and Palle Petersen. Their work appears in journals such as Thrombosis and Haemostasis, Clinical Pharmacokinetics, Journal of the American Society of Nephrology, Stroke and Annals of Noninvasive Electrocardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact